Axios reports that the federal 340B drug pricing program—an $81 billion lifeline for safety-net providers—is facing mounting pressure from major pharmaceutical companies and new federal policy shifts. Stephanie Krenrich, who leads policy and government affairs at Advocates for Community Health, was recently interviewed for the article by Maya Goldman.
Drugmakers like Eli Lilly and Novo Nordisk recently introduced new data-reporting requirements tied to discounted drug purchases. Manufacturers say these measures are meant to prevent duplicate discounts and improve oversight. But for providers, the changes represent a significant new burden—one that could undermine the very purpose of the program.
At the same time, federal policymakers are considering broader structural changes, including a shift to rebate-based pricing and potential cuts to Medicare payments tied to 340B drugs. These developments come amid increased scrutiny of the program’s rapid growth and how savings are distributed.
For community health centers, the stakes are especially high. 340B savings are not profit—they are reinvested directly into patient care, helping fund essential services for underserved communities.
“The confluence of changes in the 340B program adds fuel to the fire, and could mean health centers have to cut services, cut hours, or even close their doors,” said Krenrich.
Her warning underscores what’s at risk: not just a policy debate, but access to care for millions of patients who rely on community health centers every day.